Derivation and validation of a mathematical model for predicting the response to exogenous recombinant human growth hormone (GH) in prepubertal children with idiopathic GH deficiency. KIGS International Board. Kabi Pharmacia International Growth Stu
about
Implications of a data-driven approach to treatment with growth hormone in children with growth hormone deficiency and Turner syndromeGrowth hormone treatment and adverse events in Prader-Willi syndrome: data from KIGS (the Pfizer International Growth Database).Protein markers predict body composition during growth hormone treatment in short prepubertal children.Models predicting the growth response to growth hormone treatment in short children independent of GH status, birth size and gestational age.A proteomic approach identified growth hormone-dependent nutrition markers in children with idiopathic short stature.The first-year growth response to growth hormone treatment predicts the long-term prepubertal growth response in childrenPrediction models for short children born small for gestational age (SGA) covering the total growth phase. Analyses based on data from KIGS (Pfizer International Growth Database)Factors influencing the one- and two-year growth response in children treated with growth hormone: analysis from an observational study.Early detection of growth disorders with the CrescNet system at the Leipzig treatment center.Identification of factors associated with good response to growth hormone therapy in children with short stature: results from the ANSWER Program®.Which children should receive growth hormone treatment. Cost-benefit analysis is the keyGrowth hormone (GH) provocation tests and the response to GH treatment in GH deficiencyPresenting features and long-term effects of growth hormone treatment of children with optic nerve hypoplasia/septo-optic dysplasia.Growth hormone (GH) dose-dependent IGF-I response relates to pubertal height gain.Can point doses predict volumetric dose to rectum and bladder: a CT-based planning study in high dose rate intracavitary brachytherapy of cervical carcinoma?Rational therapeutic use of growth hormone.The variability of responses to growth hormone therapy in children with short statureA Randomized Safety and Efficacy Study of Somavaratan (VRS-317), a Long-Acting rhGH, in Pediatric Growth Hormone DeficiencyA pharmacogenomic approach to the treatment of children with GH deficiency or Turner syndromeValidating genetic markers of response to recombinant human growth hormone in children with growth hormone deficiency and Turner syndrome: the PREDICT validation study.Proteins related to lipoprotein profile were identified using a pharmaco-proteomic approach as markers for growth response to growth hormone (GH) treatment in short prepubertal children.Effect of summer daylight exposure and genetic background on growth in growth hormone-deficient childrenValidation of Prediction Models for Near Adult Height in Children with Idiopathic Growth Hormone Deficiency Treated with Growth Hormone: A Belgian Registry StudyPharmacogenomics of insulin-like growth factor-I generation during GH treatment in children with GH deficiency or Turner syndrome.Identification and management of poor response to growth-promoting therapy in children with short stature.Pediatric perspective on pharmacogenomics.Growth hormone prescribing and initial BMI SDS: Increased biochemical adverse effects and costs in obese children without additional gain in height.Predicting response to growth hormone treatment.Early growth hormone treatment start in childhood growth hormone deficiency improves near adult height: analysis from NordiNet(®) International Outcome Study.Future directions: growth prediction models.Growth hormone regimens in Australia: analysis of the first 3 years of treatment for idiopathic growth hormone deficiency and idiopathic short stature.Predicting the growth response of children with idiopathic growth hormone deficiency to one year of recombinant growth hormone treatment: derivation and validation of a useful method.Pre-treatment growth and IGF-I deficiency as main predictors of response to growth hormone therapy in neural models.Prediction of height velocity of prepubertal children with growth hormone deficiency in the first year of treatment with recombinant human growth hormone.Optimizing growth hormone therapy in growth hormone deficient children: what to do in the absence of hard evidence? Commentary on Rachmiel et al.: Final height in children with idiopathic growth hormone deficiency treated with a fixed dose of recombFinal height in children with idiopathic growth hormone deficiency treated with a fixed dose of recombinant growth hormone.Age at growth hormone therapy start and first-year responsiveness to growth hormone are major determinants of height outcome in idiopathic short stature.Association of the (CA)n repeat polymorphism of insulin-like growth factor-I and -202 A/C IGF-binding protein-3 promoter polymorphism with adult height in patients with severe growth hormone deficiency.Decreased GH dose after the catch-up growth period maintains metabolic outcome in short prepubertal children with and without classic GH deficiency.Relationship between nocturnal growth hormone concentrations, serum IGF-I/IGFBP-3 levels, insulin sensitivity and GH receptor allelic variant in small for gestational age children
P2860
Q30621592-48F14281-DBAE-494C-BCAC-917171878666Q31051461-84DC60FF-E527-4A8B-AE3B-47049AC408A0Q31112413-3A604441-3513-4292-A48B-D93B6647ECDCQ33310091-16DDF529-27F9-4044-B77B-8D644C64D438Q33392421-9D074BF4-8FE8-46D2-8479-2A3897D27C88Q33399283-3ECCAF82-B1AD-4E5A-9BA5-D2CEC9B88BA1Q33917648-3E60F4B2-3E92-4C27-AE01-2721D5B48911Q34210830-27B418CD-CC47-4800-9CF6-FE823D0914FFQ34660219-D39EA9DF-06D0-404A-A782-41CA108F4086Q35200538-959310D6-9529-4CA7-B030-78EA77F077E3Q35267373-870D0B0E-A58F-4D5D-9577-118D17B0AFB4Q35277432-AF2C4C93-6E13-4110-A25D-B5E18BC861C6Q35666652-5E061EFA-A503-4146-A548-42A6C7787FB5Q35872930-45A4B170-0C79-4A64-A66C-8EBD3FD90ECBQ36324637-28B5EB69-4780-46BC-ACA9-B65F43B6659BQ36362634-2C2EE1CF-2551-461B-9E62-99FE3D7E2991Q36701011-691B6995-5611-45FD-8FC4-1B98A56B64AEQ36716066-C58DAD04-2BA9-4144-85AA-7043B330F917Q37065683-7EB1CE6D-3F53-419E-AD40-C6BE6C9B31ABQ37396148-B18F3197-C6F3-4517-85F0-D591EBEB5F8EQ37422365-B23FFDA6-CCA9-45D5-BC38-F947576AB170Q37575685-8887F029-83CD-471A-B38E-A3AF55E8E487Q37630696-8F2A6957-8C2E-42CF-AAD5-4E32016182D9Q37646786-C765A56C-9BD3-449E-BABF-ECCE5C428433Q38006057-0161A1FC-E35D-40F5-9CCC-410091B73FB2Q38162869-54DA754A-551C-47AE-903C-9963EC2938B3Q38675599-7BED3BE4-72E0-4B4A-949A-73662911A22DQ39684391-FE0C70A4-FFB9-4594-BA14-4C8C2347C849Q40093312-7873ED69-740E-40B9-AB39-6E57EED4ACBCQ40126826-E6D678D1-3C9B-4D88-B218-6C21F34A28CEQ43795536-D41B8130-9A8B-42A8-92F4-4F45B5FB5388Q45215592-211F3CE5-2263-4232-BAB5-D4183E8E9103Q45942903-55F84FBC-B90F-402E-AEF3-4C51A5185E2AQ47230545-27C4247C-C40D-4204-8876-58C01944B833Q47294658-4EF35E55-223A-429B-8CC1-C725BEA2CEE9Q47294668-CA40EB47-D301-4AFE-AA78-C7BE9577857CQ47305397-847BD7A5-A620-41F7-A62D-153200410E27Q47347593-0271C308-56D4-43AE-97A0-FD8C919122C5Q51359657-B63F8322-AC8B-413D-941C-4A5C67F75D94Q57216861-A7BA6E9D-F900-4BBC-9E6E-BF4452C73673
P2860
Derivation and validation of a mathematical model for predicting the response to exogenous recombinant human growth hormone (GH) in prepubertal children with idiopathic GH deficiency. KIGS International Board. Kabi Pharmacia International Growth Stu
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Derivation and validation of a ...... macia International Growth Stu
@en
type
label
Derivation and validation of a ...... macia International Growth Stu
@en
prefLabel
Derivation and validation of a ...... macia International Growth Stu
@en
P2093
P356
P1476
Derivation and validation of a ...... macia International Growth Stu
@en
P2093
P304
P356
10.1210/JC.84.4.1174
P407
P577
1999-04-01T00:00:00Z